FDA Approved: EDEX — Supplemental Application (Endo USA, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for EDEX (alprostadil) from Endo USA, Inc., indicating changes to the product’s labeling under NDA 020649.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erectile Dysfunction
• Patent Ductus Arteriosus

Drugs mentioned

• EDEX (ALPROSTADIL)

Snippet

SUPPL AP for EDEX (ALPROSTADIL)